Skip to main content

Table 2 Five studies assessing the safety of ivermectin during pregnancy compared with community based controls

From: Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety

Reference Country Number of pregnant women Number inadvertently treated In the first trimester Pregnancy outcome Child mortality Child development
Pacque et al. [81] Liberia 939 200 171 (85%) No difference with controls No difference with controls No difference with controls (follow-up 2 years)
Doumbo et al. [102] Mali 461 82 Not stated Data not readily assessable
Chippaux et al. [103] Cameroon 511 110 (93) 85% No difference with controls No difference with controls No difference with controls (follow-up 1 year)
Gyapong et al. [104] Ghana 343 50 (50) 100% No difference with controls No difference with controls No difference with controls (follow-up not stated)
Ndyomugyenyi et al. [105] Uganda 834 397a All in 2nd trimester No difference with controls No difference with controls Not included
  1. a Clinical trial